Biopharmaceutical drug development: from CMC to clinical PK

An overview of Gyrolab immunoassays and their utility in CMC target binding assays for batch release and stability assessment. Also, for preclinical and clinical PK analysis with a view to transferring assays to a CRO.

This webinar will give an overview of a Gyrolab system and how it is used to support biopharmaceutical drug development. Uses include bioprocess application and pharmacokinetic assays. A case study from Symphogen will highlight how a Gyrolab 2-plex assay can be used to support a program for a therapeutic antibody mixture. The case study will highlight the advantages of speed, data quality and ease of transferring an assay to a CRO.

What will you learn?

  • How to maximize the performance and productivity of automated ligand-binding assays
  • How automated ligand-binding assays of two monoclonal antibodies can lead to efficient assay development and validation
  • How transferring a ligand-binding assay to a CRO can be made easier



rikke hald-1
Rikke Hald, MSc, PhD
Senior Scientist, Bioassays
Symphogen A/S (Ballerup, Denmark)


If you have problems to view the webinar please contact


Please register to view the webinar